Gerrina Ruiter
WCLC 2024 - Gerrina Ruiter Gerrina Ruiter dives i
WCLC 2024 - Gerrina Ruiter Gerrina Ruiter dives i
Refining treatment approaches in early-stage lung canc
WCLC 2024 - Diego Kauffmann-Guerrero Diego Kauffm
Innovative treatment approaches: non–EGFR-directed bis
HER2 aberrations and other oncogenic drivers HER2 mu
Concurrent MET/EGFR inhibition and third-generat
Preface – WCLC 2024 Professor Benjamin Solomon MBB
WCLC 2024 - Pascale Tomasini Pascale Tomasini dis
WCLC 2024 - Andrea R. Filippi Andrea R. Filippi t
Economic analysis of zanubrutinib vs. acalabrutinib in